Skip to main content

Faslodex News

Neratinib, Fulvestrant, Trastuzumab Combo Aids Metastatic Breast Cancer

TUESDAY, Nov. 28, 2023 – For patients with hormone receptor (HR)-positive HER2-mutant metastatic breast cancer (MBC) with progression on cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy,...

Faslodex (fulvestrant) Receives FDA Approval as Monotherapy for Expanded Use in HR+, HER2- Advanced Breast Cancer

August 28, 2017 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Faslodex (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor...

FDA Approves New Dosing for Faslodex (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women

WILMINGTON, Del., Sept. 10 /PRNewswire-FirstCall/ – AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of Faslodex (fulvestrant) Injection,...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Breast Cancer, Metastatic, Breast Cancer

Faslodex patient information at Drugs.com